Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-021479
Filing Date
2025-02-14
Accepted
2025-02-14 17:22:49
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 14936
  Complete submission text file 0000950170-25-021479.txt   16866
Mailing Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248
Business Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248 214.866.0202
Anson Funds Management LP (Filed by) CIK: 0001491072 (see all company filings)

EIN.: 300134498 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Subject) CIK: 0001716947 (see all company filings)

EIN.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90218 | Film No.: 25631068
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)